Drug Profile
Research programme: porphyrin-based cancer therapeutics - OncoSelect Therapeutics
Latest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator OncoSelect Therapeutics
- Developer OncoSelect Therapeutics; University of Texas Health Science Center at San Antonio
- Class Porphyrins
- Mechanism of Action Image enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 15 May 2023 Early research development is ongoing in USA
- 15 May 2023 OncoSelect Therapeutics has patent protection for patent related to "Porphyrin Compounds and Compositions to Treat Cancer" in Hong Kong, China and Mexico
- 15 May 2023 OncoSelect Therapeutics has patents pending for patent related to "Porphyrin Compounds and Compositions to Treat Cancer" in Canada, the European Union, India and Japan